Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

Also called NCT01982292

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking
Phase
Phase 2
Enrolled
  • 321 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01982292
  • EudraCT 2013-002781-39
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Czechia, Finland, Germany, Italy, Netherlands, Norway, Romania, Russia, Spain, Sweden, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01982292. Randomized; quadruple masking. Start 2014-05 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-11-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
Acronym
RELAX-REPEAT
Condition
Chronic Heart Failure
Intervention (Drug)
RLX030 (serelaxin)
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01982292
Content hash
09d767826c738fe4738d8429e8d1ccc5970c85f7bb87bfd33fa503b3209e58d3